Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF

Table 4 Univariate and multivariate Cox proportional hazard model evaluating predictors of disease progression

Variables	β	HR	(95% CI)	p value
Univariate analysis
Age at diagnosis (continuous)	0.025	1.026	0.991–1.062	0.152
Gender (male)	0.001	1.001	0.385–2.606	0.998
Smoking history (non smoker)	− 0.663	0.515	0.060–4.437	0.546
CCI** (> 3)	0.873	1.011	0.260–2.406	0.842
BMI (continuous)	0.028	1.029	0.951–1.113	0.481
FVC % pred (continuous)	0.018	1.018	1.002–1.034	0.027
PaO₂ mmHg (continuous)	0.016	1.016	0.982–1.052	0.363
DLco % pred (continuous)	0.002	1.002	0.977–1.028	0.884
Antifibrotic treatment (yes)	0.669	1.602	0.952–3.004	0.068
MUC5B (T allele)	− 1.378	0.252	0.034–1.862	0.177
TOLLIP rs5743890 (C/T genotype)	0.923	3.517	1.276–5.964	0.008
TOLLIP rs3750920 (T allele)	− 0.136	0.873	0.290–2.626	0.809
Multivariate analysis*
TOLLIP rs5743890 (C/T genotype)	1.082	2.949	1.327–6.556	0.008

*Model obtained by using backward conditional stepwise regression (11 steps), including age, gender, smoking status, BMI and antifibrotic treatment as covariates
**Charlson Comorbidity Index

ISSN: 1750-1172